Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study.
暂无分享,去创建一个
L. Golberg | J. D. Chapman | A. McEwan | L. Wiebe | M. Parliament | R. Urtasun | L. Golberg | J. Mercer | R. H. Mannan | R. C. Urtasun | M. B. Parliament | A. J. McEwan | J. R. Mercer | L. I. Wiebe | J. Chapman | Jd Chapman | RC Urtasun | AJ McEwan | JR Mercer | RH Mannan | LI Wiebe | Mb Parliament
[1] A. J. Varghese,et al. Detection of a reactive metabolite of misonidazole in hypoxic mammalian cells. , 1984, Radiation research.
[2] K. Krohn,et al. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. , 1989, International journal of radiation oncology, biology, physics.
[3] C. J. Koch,et al. A novel technique for measuring human tissue pO2 at the cellular level. , 1986, British Journal of Cancer.
[4] J. Lee,et al. Keynote address: cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells. , 1989, International journal of radiation oncology, biology, physics.
[5] J. D. Chapman,et al. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. , 1983, Cancer research.
[6] V. R. McCready,et al. Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours. , 1989, British Journal of Cancer.
[7] B. Garrecht,et al. The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole. , 1983, The British journal of radiology.
[8] J. Lee,et al. Adduct Formation by 2-Nitroimidazole Drugs in Mammalian Cells: Optimization of Markers for Tissue Oxygenation , 1990 .
[9] J. Henk,et al. RADIOTHERAPY AND HYPERBARIC OXYGEN IN HEAD AND NECK CANCER Interim Report of Second Clinical Trial , 1977, The Lancet.
[10] J. D. Chapman,et al. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] L. M. Cobb,et al. Tissue distribution of 14C- and 3H-labelled misonidazole in the tumor-bearing mouse. , 1990, International journal of radiation oncology, biology, physics.
[12] A. Franko. Misonidazole and other hypoxia markers: metabolism and applications. , 1986, International journal of radiation oncology, biology, physics.
[13] A J Dembo,et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. , 1978, The British journal of cancer. Supplement.
[14] P. Okunieff,et al. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.
[15] J. D. Chapman,et al. A marker for hypoxic cells in tumours with potential clinical applicability. , 1981, British Journal of Cancer.
[16] P. Band,et al. Radiation and high-dose metronidazole in supratentorial glioblastomas. , 1976, The New England journal of medicine.
[17] L. Wiebe,et al. Iodoazomycin Riboside [l-(5′-iodo-5′- deoxyribofuranosyl)-2-nitroimidazolel, a Hypoxic Cell Marker In Vivo Evaluation in Experimental Tumors , 1986 .
[18] R. Gatenby,et al. Oxygen tension in human tumors: in vivo mapping using CT-guided probes. , 1985, Radiology.
[19] L. Wiebe,et al. Iodoazomycin riboside (1-(5'-iodo-5'-deoxyribofuranosyl)-2-nitroimidazole), a hypoxic cell marker. I. Synthesis and in vitro characterization. , 1986, Radiation research.
[20] R. Gatenby,et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. , 1988, International journal of radiation oncology, biology, physics.